SPONSOR
Beijing GoBroad Hospital
Total Trials
7
Recruiting
7
Phases
Phase 1, Phase 2, EARLY_Phase 1, Phase 1
Conditions studied: Refractory Lupus NephritisSystemic SclerosisPrimary Sjogren's Syndrome Combined With Pulmonary HypertensionB-cell Non-Hodgkin Lymphoma Recurrent B-cell Non-Hodgkin Lymphoma RefractoryGastroesophageal Junction AdenocarcinomaSystemic Sclerosis (SSc)Primary Sjogren's SyndromeT-Cell Acute Lymphocytic LeukemiaAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic Leukemia
Beijing GoBroad Hospital is a clinical research sponsor with 7 registered studies on ClinicalTrials.gov, of which 7 are actively recruiting participants. Research covers conditions including Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension, B-cell Non-Hodgkin Lymphoma Recurrent B-cell Non-Hodgkin Lymphoma Refractory.
The trial portfolio spans Phase 1, Phase 2, EARLY_Phase 1, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Beijing GoBroad Hospital
How many clinical trials has Beijing GoBroad Hospital sponsored?
ClinicalMetric currently tracks 7 clinical trials sponsored by Beijing GoBroad Hospital, of which 7 are actively recruiting participants. These trials cover conditions including Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Beijing GoBroad Hospital research focus on?
Beijing GoBroad Hospital clinical trials span Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension, B-cell Non-Hodgkin Lymphoma Recurrent B-cell Non-Hodgkin Lymphoma Refractory, Gastroesophageal Junction Adenocarcinoma, and additional conditions. The research pipeline includes Phase 1, Phase 2, EARLY_Phase 1, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Beijing GoBroad Hospital clinical trial?
To participate in a Beijing GoBroad Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Beijing GoBroad Hospital trials with current recruitment status updated daily.
Clinical Trials by Beijing GoBroad Hospital
NCT06947473 Phase 1, Phase 2
Recruiting
Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
Refractory Lupus Nephritis
NCT07093411 EARLY_Phase 1
Recruiting
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
B-cell Non-Hodgkin Lymphoma Recurrent B-cell Non-Hodgkin Lymphoma Refractory
NCT07179484
Recruiting
To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
NCT07167537 Phase 1
Recruiting
A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases
Systemic Sclerosis (SSc)
NCT06947460 Phase 1, Phase 2
Recruiting
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
Refractory Lupus Nephritis
NCT07070323 Phase 1, Phase 2
Recruiting
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
T-Cell Acute Lymphocytic Leukemia
NCT06343090
Recruiting
Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
B-cell Acute Lymphoblastic Leukemia
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology